JACK-MA/ALIBABA-FOUND
26.3.2020 04:45:09 CET | Business Wire | Press release
Over 440 medical institutions from 104 countries and regions have applied to learn and share experiences in battling COVID-19 through the International Medical Expert Communication Platform . The Handbook of COVID-19 Prevention and Treatment is now available in seven languages with more to come.
The platform, a centerpiece of the Global MediXchange for Combating COVID-19 (GMCC) program, was jointly established by the Jack Ma Foundation and Alibaba Foundation. It is designed for medical experts around the world to communicate seamlessly with each other to share their invaluable experience of fighting coronavirus disease 2019 (COVID-19) and to ask and answer each other’s questions. To date, the most applications have come in thus far from medical institutions in the U.S, Turkey, the U.K., Pakistan, Spain and Germany.
Medical staff need to apply and be approved to join the platform. Once they’re accepted, they’re free to participate in individual or group discussions and sessions.
“Knowledge is power! We launched an online platform for doctors and nurses around the world to exchange ideas, lessons and know-how to fight the virus. We welcome all hospitals to join Chinese hospitals on this open platform https://covid-19.alibabacloud.com . One world, one fight!" Jack Ma wrote in a tweet Wednesday.
Tapping Alibaba Group’s DingTalk messaging and communications functions, the digital platform provides free audio and video conference functionality, along with live broadcast functions for more-complex scenarios. Medical workers from different countries can choose to communicate with their fellow doctors individually, or they can participate in live-sharing group sessions to interact with multiple participants, using real-time artificial intelligence translation to overcome communication barriers. The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), for example, has been using the platform to share their valuable experience with 92 medical institutions from 44 countries and regions.
A playback function allows further sharing or posting on official websites for consumption anytime – and for those who can’t join the live broadcasts due to the time difference or if they are occupied by their duties.
To date, the International Medical Expert Communication Platform has attracted numerous Chinese medical institutions, including Zhongnan Hospital of Wuhan University (Wuhan Leishenshan Hospital), The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), and others.
Through video conferencing and AI translation from and into 11 languages (Arabic, Chinese, English, French, Indonesian, Japanese, Russian, Spanish, Thai, Turkish, and Vietnamese), the platform aims to build a virtual community.
DingTalk, which powers this platform, has also been tabbed by UNESCO as facilitating distance learning during the coronavirus outbreak.
Also as part of the GMCC programme, the Handbook of COVID-19 Prevention and Treatment , authored by The First Affiliated Hospital, Zhejiang University School of Medicine and compiled according to clinical experience, is now available at no cost in Chinese, English, French, Italian, Japanese, Turkish and Spanish. This handbook provides comprehensive guidelines and best practices by China's top experts for coping with COVID-19. More languages will be added soon, as the GMCC programme continues to launch more anti-epidemic resources and provide more practical suggestions and references for medical staff worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005799/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom